Werewolf Therapeutics (HOWL) Other Non Operating Income (2020 - 2026)
Werewolf Therapeutics (HOWL) posted quarterly Other Non Operating Income of -$3.4 million for Q2 2026, down 30590.91% year-over-year from N/an in Q2 2025, and down 597.63% on a QoQ basis from $674000.0 in Q1 2026.
Werewolf Therapeutics (HOWL) Other Non Operating Income (2020 - 2026) Analysis & Trends
Werewolf Therapeutics has reported Other Non Operating Income for 7 years, with the latest figure at -$3.4 million in Q2 2026.
- Other Non Operating Income for Q2 2026 came in at -$3.4 million, down 30590.91% year-over-year; the trailing twelve-month figure through Jun 2026 was -$838000.0 (down 560.44% YoY), and the FY2025 annual result was $2.0 million, up 25.14% from the prior year.
- Other Non Operating Income slipped to -$3.4 million in Q2 2026, from $674000.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $1.8 million in Q4 2025 and troughed at -$3.4 million in Q2 2026.
- A 5-year average of -$121235.3 and a median of -$1000.0 in 2024 frame the typical range for Other Non Operating Income.
- The widest annual swing landed in 2025, when Other Non Operating Income jumped 16900.0%; it then slumped 30590.91% in 2026.
- A 5-year view of Other Non Operating Income shows it stood at $70000.0 in 2022, then tumbled by 108.57% to -$6000.0 in 2023, then sank by 1466.67% to -$94000.0 in 2024, then jumped by 2059.57% to $1.8 million in 2025, then sank by 282.08% to -$3.4 million in 2026.
- Per Business Quant data, the three most recent Other Non Operating Income figures were -$3.4 million in Q2 2026, $674000.0 in Q1 2026, and $1.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Werewolf Therapeutics | 43.94 Mn | 43.94 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.35 Mn |
| Mar 31, 2026 | 674,000.00 |
| Dec 31, 2025 | 2.02 Mn |
| Jun 30, 2025 | 11,000.00 |
| Mar 31, 2025 | 168,000.00 |
| Dec 31, 2024 | -2.26 Mn |
| Jun 30, 2024 | -600,000.00 |
| Mar 31, 2024 | -1,000.00 |
| Dec 31, 2023 | -6,000.00 |
| Jun 30, 2023 | -25,000.00 |
| Mar 31, 2023 | -1.11 Mn |
| Dec 31, 2022 | 70,000.00 |
| Sep 30, 2022 | 3,000.00 |
| Jun 30, 2022 | 281,000.00 |
| Mar 31, 2022 | -16,000.00 |
| Sep 30, 2021 | -17,000.00 |
| Jun 30, 2021 | -16,000.00 |
| Mar 31, 2021 | -16,000.00 |
| Jun 30, 2020 | -3,000.00 |